Open AccessTreatment of biliary tract cancer with NVP-AEW541: Mechanisms of action and resistance
Author(s) -
Samuel Wolf,
Jana Lorenz,
Joachim Mössner,
Marcus Wiedmann
Publication year - 2010
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v16.i2.156
Subject(s) - gemcitabine , cancer research , autocrine signalling , protein kinase b , insulin like growth factor , cell growth , cell cycle , cancer , growth factor , biology , signal transduction , medicine , receptor , microbiology and biotechnology , biochemistry
To investigate in vitro treatment with NVP-AEW541, a small molecule inhibitor of insulin-like growth factor-1 receptor (IGF-1R), in biliary tract cancer (BTC), since this disease is associated with a poor prognosis due to wide resistance to chemotherapeutic agents and radiotherapy.